Form 4: Werewolf Therapeutics Director Sells Shares

A director and 10% owner of Werewolf Therapeutics, Luke Evnin, reported the sale of 48,171 shares of common stock over three days in December 2025.

Summary

• Luke Evnin, a Director and 10% owner of Werewolf Therapeutics, Inc. (HOWL), reported sales of common stock.
• Transactions occurred on December 15, 16, and 17, 2025, under a Rule 10b5-1 plan established on September 24, 2025.
• On December 15, 2025, 23,640 shares were sold at a weighted average price of $1.07, with prices ranging from $1.02 to $1.10.
• On December 16, 2025, 14,548 shares were sold at a weighted average price of $1.05, with prices ranging from $1.02 to $1.10.
• On December 17, 2025, 9,983 shares were sold at a weighted average price of $1.14, with prices ranging from $1.095 to $1.18.
• Following these transactions, the reporting person indirectly beneficially owns 2,841,957 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can be viewed negatively, the existence of a 10b5-1 plan mitigates concerns that the sales are based on new, negative material information. It's a pre-planned event for personal financial management.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating they were not a reaction to recent negative news or a sudden loss of confidence.

Negatives

• A director and significant owner reducing their stake could be perceived negatively by the market, even if pre-planned.
• The sales occurred at relatively low prices, ranging from $1.02 to $1.18 per share.

Risks

• Investor perception risk: Sales by insiders, even if pre-planned, can sometimes be interpreted as a lack of confidence in the company's future prospects, potentially leading to downward pressure on the stock price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure for a director of a publicly traded biotechnology company. While the sale of shares by a director can sometimes raise questions, the execution under a Rule 10b5-1 plan suggests a pre-determined selling strategy rather than a reaction to specific industry events or company performance. Such plans are common among executives and directors for personal financial planning and diversification.

Comparison to Industry Standards

• NA

Related Party Transactions

• The transactions involve sales by entities where Luke Evnin has an indirect interest (e.g., MPM Asset Management LLC, MPM BioVentures 2014, L.P.), which are disclosed as part of his beneficial ownership. These are standard disclosures for insider transactions involving investment vehicles.

Stakeholder Impact

• Shareholders: May perceive the sales as a slight negative due to a director reducing their stake, but the 10b5-1 plan context should temper significant concern.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this routine insider transaction.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

The insider sales by Director Luke Evnin, while reducing his indirect stake, were conducted under a pre-established Rule 10b5-1 plan. This suggests the sales are for personal financial planning and diversification rather than a reflection of new, adverse company-specific information. Without additional context on the company's operational performance or strategic direction, these routine insider sales do not provide a strong basis for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while awaiting further fundamental updates.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Biotechnology, SEC Filing